Florida Regulations 64E-5.627: Use of Unsealed Radiopharmaceuticals, Generators, and Reagent Kits for Imaging and Localization Studies
Current as of: 2024 | Check for updates
|
Other versions
A licensee is allowed to use any radioactive material in a diagnostic radiopharmaceutical, or any generator, or reagent kit, for preparation and diagnostic use of a radiopharmaceutical containing radioactive material for medical use under the following conditions:
(1) When a written directive is not required by subsection 64E-5.607(3), F.A.C., the licensee must satisfy the following:
(a) Obtained from a manufacturer or pharmacy licensed as specified in subsection 64E-5.210(10), F.A.C., or in equivalent U.S. Nuclear Regulatory Commission or Agreement State regulations, or
(b) Radioactive material is obtained from and prepared by a NRC or agreement state licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an IND protocol accepted by FDA, or
(c) Radioactive material is prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application or an IND protocol accepted by FDA, or
(d) Radioactive material is prepared by:
1. An authorized nuclear pharmacist,
2. Except for sodium iodide I-131 in quantities greater than 30 microcuries (1.11 MBq), a physician who is an authorized user and meets the training requirements specified in Rules 64E-5.650 or 64E-5.660 and sub-subFl. Admin. Code R. 64E-5.650(3)(a)2.g., or
3. An individual under the supervision of a physician who is an authorized user under subFl. Admin. Code R. 64E-5.626(1)(d)2., and as specified in paragraphs 64E-5.601(3)(a) and (b), 64E-5.607(3)(e) or subsection 64E-5.608(1), F.A.C., or
(e) The authorized user must satisfy the training and experience specified in Rule 64E-5.650 or 64E-5.657, F.A.C.
(2) When a written directive is required by subsection 64E-5.607(3), F.A.C., the licensee must satisfy the following:
(a) Radioactive material is obtained from a manufacturer or pharmacy licensed as specified in subsection 64E-5.210(10), F.A.C., or in equivalent NRC or agreement state regulations, or
(b) Radioactive material is obtained from and prepared by an NRC or agreement state licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an IND protocol accepted by FDA, or
(c) Radioactive material is prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application or an IND protocol accepted by FDA, or
(d) Radioactive material is prepared by:
1. An authorized nuclear pharmacist,
2. A physician who is an authorized user and meets the training requirements specified in Rule 64E-5.650 or 64E-5.660, F.A.C., or
3. An individual under the supervision of a physician who is an authorized user under subFl. Admin. Code R. 64E-5.627(2)(d)2., and as specified in paragraphs 64E-5.601(3)(a) and (b), 64E-5.607(3)(e) or subsection 64E-5.608(1), F.A.C.
(e) The authorized user must satisfy the applicable training and experience specified in Rules 64E-5.657, 64E-5.660, 64E-5.661, 64E-5.662 or 64E-5.663, F.A.C.
(3) For oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries (1.22 gigabecquerels) and when a written directive is required by subsection 64E-5.607(3), F.A.C., the licensee must satisfy the following:
(a) Radioactive material is obtained from a manufacturer or pharmacy licensed as specified in subsection 64E-5.210(10), F.A.C., or in equivalent NRC or agreement state regulations, or
(b) Radioactive material is obtained from and prepared by a NRC or agreement state licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an IND protocol accepted by FDA, or
(c) Radioactive material is prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application or an IND protocol accepted by FDA, or
(d) Radioactive material is prepared by:
1. An authorized nuclear pharmacist,
2. A physician who is an authorized user and meets the training requirements specified in Rule 64E-5.650 or 64E-5.660, F.A.C.,
3. An individual under the supervision of a physician who is an authorized user under subFl. Admin. Code R. 64E-5.627(1)(d)2., and as specified in paragraphs 64E-5.601(3)(a) and (b), 64E-5.607(3)(e) or subsection 64E-5.608(1), F.A.C.
(e) The authorized user must satisfy the applicable training and experience specified in Rules 64E-5.657, 64E-5.660 or 64E-5.661, F.A.C.
(4) A licensee shall use radioactive aerosols or gases only if application on DH Form 1322 12/09 is made to and approved by the department and the requirements of Fl. Admin. Code R. 64E-5.629, are met.
Rulemaking Authority 404.051, 404.061, 404.071, 404.081, 404.141 FS. Law Implemented 404.022, 404.051(1), (4), (5), (6), (8), (9), (10), (11), 404.061(2), (3), 404.071(1), 404.081, 404.141 FS. History-New 8-25-91, Amended 5-12-93, Formerly 10D-91.735, Amended 8-6-01, 2-11-10, 12-26-13.
(a) Obtained from a manufacturer or pharmacy licensed as specified in subsection 64E-5.210(10), F.A.C., or in equivalent U.S. Nuclear Regulatory Commission or Agreement State regulations, or
(b) Radioactive material is obtained from and prepared by a NRC or agreement state licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an IND protocol accepted by FDA, or
(c) Radioactive material is prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application or an IND protocol accepted by FDA, or
(d) Radioactive material is prepared by:
1. An authorized nuclear pharmacist,
2. Except for sodium iodide I-131 in quantities greater than 30 microcuries (1.11 MBq), a physician who is an authorized user and meets the training requirements specified in Rules 64E-5.650 or 64E-5.660 and sub-subFl. Admin. Code R. 64E-5.650(3)(a)2.g., or
3. An individual under the supervision of a physician who is an authorized user under subFl. Admin. Code R. 64E-5.626(1)(d)2., and as specified in paragraphs 64E-5.601(3)(a) and (b), 64E-5.607(3)(e) or subsection 64E-5.608(1), F.A.C., or
(e) The authorized user must satisfy the training and experience specified in Rule 64E-5.650 or 64E-5.657, F.A.C.
(2) When a written directive is required by subsection 64E-5.607(3), F.A.C., the licensee must satisfy the following:
(a) Radioactive material is obtained from a manufacturer or pharmacy licensed as specified in subsection 64E-5.210(10), F.A.C., or in equivalent NRC or agreement state regulations, or
(b) Radioactive material is obtained from and prepared by an NRC or agreement state licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an IND protocol accepted by FDA, or
(c) Radioactive material is prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application or an IND protocol accepted by FDA, or
(d) Radioactive material is prepared by:
1. An authorized nuclear pharmacist,
2. A physician who is an authorized user and meets the training requirements specified in Rule 64E-5.650 or 64E-5.660, F.A.C., or
3. An individual under the supervision of a physician who is an authorized user under subFl. Admin. Code R. 64E-5.627(2)(d)2., and as specified in paragraphs 64E-5.601(3)(a) and (b), 64E-5.607(3)(e) or subsection 64E-5.608(1), F.A.C.
(e) The authorized user must satisfy the applicable training and experience specified in Rules 64E-5.657, 64E-5.660, 64E-5.661, 64E-5.662 or 64E-5.663, F.A.C.
(3) For oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries (1.22 gigabecquerels) and when a written directive is required by subsection 64E-5.607(3), F.A.C., the licensee must satisfy the following:
(a) Radioactive material is obtained from a manufacturer or pharmacy licensed as specified in subsection 64E-5.210(10), F.A.C., or in equivalent NRC or agreement state regulations, or
(b) Radioactive material is obtained from and prepared by a NRC or agreement state licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an IND protocol accepted by FDA, or
(c) Radioactive material is prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application or an IND protocol accepted by FDA, or
(d) Radioactive material is prepared by:
1. An authorized nuclear pharmacist,
2. A physician who is an authorized user and meets the training requirements specified in Rule 64E-5.650 or 64E-5.660, F.A.C.,
3. An individual under the supervision of a physician who is an authorized user under subFl. Admin. Code R. 64E-5.627(1)(d)2., and as specified in paragraphs 64E-5.601(3)(a) and (b), 64E-5.607(3)(e) or subsection 64E-5.608(1), F.A.C.
(e) The authorized user must satisfy the applicable training and experience specified in Rules 64E-5.657, 64E-5.660 or 64E-5.661, F.A.C.
(4) A licensee shall use radioactive aerosols or gases only if application on DH Form 1322 12/09 is made to and approved by the department and the requirements of Fl. Admin. Code R. 64E-5.629, are met.
Rulemaking Authority 404.051, 404.061, 404.071, 404.081, 404.141 FS. Law Implemented 404.022, 404.051(1), (4), (5), (6), (8), (9), (10), (11), 404.061(2), (3), 404.071(1), 404.081, 404.141 FS. History-New 8-25-91, Amended 5-12-93, Formerly 10D-91.735, Amended 8-6-01, 2-11-10, 12-26-13.